Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Tango Therapeutics, Inc.
Novartis
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Tango Therapeutics, Inc.
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Bayer
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Turning Point Therapeutics, Inc.
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
Eastern Cooperative Oncology Group
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Hoffmann-La Roche
Institut Bergonié
City of Hope Medical Center
Aveni Foundation
University of California, Irvine
M.D. Anderson Cancer Center
ViroMissile, Inc.
Dana-Farber Cancer Institute
Kaiser Permanente
Washington University School of Medicine
University of Florida
Essen Biotech
MacroGenics
Indiana University
City of Hope Medical Center
Duke University
Fred Hutchinson Cancer Center
University of Nebraska
Adela, Inc
Perspective Therapeutics
M.D. Anderson Cancer Center